Promis Neurosciences (PMN) Competitors $0.50 +0.03 (+6.36%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$0.48 -0.01 (-2.81%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMN vs. COYA, ALXO, IMUX, IFRX, PLRX, IZTC, LITS, WHWK, ENTX, and APLTShould you be buying Promis Neurosciences stock or one of its competitors? The main competitors of Promis Neurosciences include Coya Therapeutics (COYA), ALX Oncology (ALXO), Immunic (IMUX), InflaRx (IFRX), Pliant Therapeutics (PLRX), Invizyne Technologies (IZTC), Lite Strategy (LITS), Whitehawk Therapeutics (WHWK), Entera Bio (ENTX), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical products" industry. Promis Neurosciences vs. Its Competitors Coya Therapeutics ALX Oncology Immunic InflaRx Pliant Therapeutics Invizyne Technologies Lite Strategy Whitehawk Therapeutics Entera Bio Applied Therapeutics Coya Therapeutics (NASDAQ:COYA) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability. Do analysts rate COYA or PMN? Coya Therapeutics currently has a consensus target price of $16.20, suggesting a potential upside of 165.57%. Promis Neurosciences has a consensus target price of $4.33, suggesting a potential upside of 770.15%. Given Promis Neurosciences' higher possible upside, analysts plainly believe Promis Neurosciences is more favorable than Coya Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67Promis Neurosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals & insiders have more ownership in COYA or PMN? 39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 12.0% of Coya Therapeutics shares are held by company insiders. Comparatively, 6.1% of Promis Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, COYA or PMN? Coya Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Promis Neurosciences has a beta of -0.17, indicating that its stock price is 117% less volatile than the S&P 500. Is COYA or PMN more profitable? Coya Therapeutics' return on equity of -61.05% beat Promis Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Coya TherapeuticsN/A -61.05% -53.61% Promis Neurosciences N/A -266.69%-131.59% Does the media prefer COYA or PMN? In the previous week, Coya Therapeutics had 12 more articles in the media than Promis Neurosciences. MarketBeat recorded 13 mentions for Coya Therapeutics and 1 mentions for Promis Neurosciences. Coya Therapeutics' average media sentiment score of 0.36 beat Promis Neurosciences' score of -1.00 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Coya Therapeutics Neutral Promis Neurosciences Negative Which has better valuation and earnings, COYA or PMN? Promis Neurosciences has lower revenue, but higher earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$423.45K240.93-$14.88M-$1.24-4.92Promis NeurosciencesN/AN/A$2.78M-$0.21-2.37 SummaryCoya Therapeutics beats Promis Neurosciences on 9 of the 14 factors compared between the two stocks. Get Promis Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMN vs. The Competition Export to ExcelMetricPromis NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.80M$3.35B$6.11B$10.54BDividend YieldN/A2.28%5.66%4.70%P/E Ratio-2.3722.2886.9326.71Price / SalesN/A265.40529.88204.42Price / CashN/A46.3226.3031.09Price / Book1.009.9012.746.57Net Income$2.78M-$52.45M$3.30B$276.78M7 Day Performance13.18%5.05%3.55%1.98%1 Month Performance15.81%10.61%6.79%9.13%1 Year Performance-54.31%25.03%73.23%31.60% Promis Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMNPromis Neurosciences2.634 of 5 stars$0.50+6.4%$4.33+770.1%-54.3%$26.80MN/A-2.375Negative NewsCOYACoya Therapeutics2.6943 of 5 stars$5.70+0.7%$16.20+184.2%-16.0%$94.66M$3.55M-4.606ALXOALX Oncology3.6516 of 5 stars$1.83+4.6%$3.30+80.3%+29.8%$93.71MN/A-0.8340IMUXImmunic2.5104 of 5 stars$0.88-5.7%$9.50+977.6%-39.2%$92.22MN/A-0.9470IFRXInflaRx2.2547 of 5 stars$1.34-2.2%$6.20+362.7%+1.3%$91.97M$162.83K-1.6760Short Interest ↑PLRXPliant Therapeutics3.81 of 5 stars$1.48-0.7%$8.19+453.2%-86.8%$91.47M$1.58M-0.4490IZTCInvizyne TechnologiesN/A$14.50-6.3%N/AN/A$90.65MN/A0.0029LITSLite StrategyN/A$2.42-4.7%N/AN/A$90.56M$65.30M0.00100News CoveragePositive NewsAnalyst UpgradeGap DownWHWKWhitehawk TherapeuticsN/A$1.90-1.0%N/AN/A$90.49M$25.98M-31.6721Positive NewsENTXEntera Bio1.6126 of 5 stars$1.92-1.5%$10.00+420.8%+1.6%$89.04M$166K-7.3820APLTApplied Therapeutics3.6889 of 5 stars$0.60-1.1%$4.13+581.9%-87.0%$88.12M$121K-1.3430 Related Companies and Tools Related Companies Coya Therapeutics Alternatives ALX Oncology Alternatives Immunic Alternatives InflaRx Alternatives Pliant Therapeutics Alternatives Invizyne Technologies Alternatives Lite Strategy Alternatives Whitehawk Therapeutics Alternatives Entera Bio Alternatives Applied Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMN) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThis soon could be the most precious company in AmericaCurrently, a brand-new, all-American factory outside San Antonio is becoming the most significant site in the ...True Market Insiders | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Promis Neurosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Promis Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
